Ningbo Yunsheng: Has Submitted an Application for H-Share Issuance and Listing to the Hong Kong Stock Exchange
Ningbo Yun Sheng has submitted an application to the Hong Kong Stock Exchange for an H-share issuance and listing. Separately, Innovent Biologics has entered into an exclusive licensing agreement with Dimerix Limited to develop and commercialize DMX-200 in Greater China, South Korea, and parts of Southeast Asia. DMX-200 is a small molecule inhibitor targeting CCR2 and is currently in Phase 3 clinical trials for focal segmental glomerulosclerosis, having received Orphan Drug designation from the FDA and EMA. AI
IMPACT This cluster is not directly related to AI.